Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK on track to deliver 2024 outlooks with further good progress made in R&D
Q3 2024 performance highlights
-
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
Agreement reinforces GSK’s portfolio in the treatment of lupus and underlying drivers of autoimmune disease
Download (PDF, 134.6KB) -
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Download (PDF, 244.1KB) -
GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
GSK is investing more than £50 million in the CG-TIC to further accelerate research and development in kidney and respiratory diseases.
Download (PDF, 128.8KB) -
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Studies from OPERA and Trio cohorts provide further real-world evidence.
Download (PDF, 271.8KB) -
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years.
Download (PDF, 206.3KB) -
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
Depemokimab is an ultra-long-acting biologic administered once every six months
Download (PDF, 199.1KB) -
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 314.0KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons.
Download (PDF, 175.4KB) -
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
At least two million doses of long-acting cabotegravir for PrEP to be made available in 2025-2026.
Download (PDF, 99.2KB) -
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion
Marketing authorisation in EU expected by November 2024.
Download (PDF, 176.5KB) -
Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
GSK confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell and Annette Hughes.
Download (PDF, 138.1KB) -
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials.
Download (PDF, 204.8KB) -
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma
Granted based on results from phase III head-to-head DREAMM-7 trial.
Download (PDF, 136.8KB) -
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
Data support progression to phase III clinical trials.
Download (PDF, 128.7KB) -
GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial
Results show that GSK3943104 did not meet the study’s primary efficacy objective.
Download (PDF, 121.3KB) -
Statement: Zantac (ranitidine) litigation – Dixon case
GSK confirmed it has reached a settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court.
Download (PDF, 112.0KB) -
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered statistically significant and clinically meaningful reduction in exacerbations
Download (PDF, 185.7KB) -
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announces positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) in adults with COPD.
Download (PDF, 170.6KB)
